HUGE רווח נקי למניה ב-12 החודשים האחרונים FSD Pharma

Trailing twelve-month earnings per share on the GURU.Markets chart shows a decline for FSD Pharma Inc. (HUGE) due to austerity measures and the liquidation of non-core assets. This results from a strategic focus on developing precision drugs for neurodegeneration and strong confidence among scientists in the company's methods for combating brain inflammation. The value of -0.26 determines the current status of the parameter, helping investors assess real profit without market noise.

For the biotech company FSD Pharma Inc. (HUGE), which focuses on developing treatments for depression and PTSD, operational efficiency is driven by clinical trial expenditures. This indicator is calculated as the ratio of annual net income to the number of non-diluted shares. The metric allows for an assessment of the real return per share by excluding the impact of issuance factors. It is critical for investors to track capital dynamics amid the optimization of the patent portfolio. Analyzing the rolling net income per share helps identify business consolidation phases in a timely manner.